Bitwise MARA Option Income Strategy 

$17.48
971
+$0.46+2.7% Monday 19:19

Statistics

Day High
17.71
Day Low
17.42
52W High
54.94
52W Low
11.99
Volume
15,941
Avg. Volume
-
Mkt Cap
1.04B
P/E Ratio
-
Dividend Yield
11.74%
Dividend
2.05

Upcoming

Dividends

11.74%Dividend Yield
Jul 26
$0.17
May 26
$0.17
Apr 26
$0.15
Mar 26
$0.25
Mar 26
$0.31
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
-91.65%

Earnings

19AugExpected
Q4 2022
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.57
-0.45
-0.32
-0.2
Expected EPS
-0.40145
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-178.05MNet Income

Analyst Ratings

59.25Average Price Target
The highest estimate is 62.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMRA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap294.03B
Merck & Co., Inc. is a global healthcare company that operates in the same oncology space, competing directly with Enliven Therapeutics' cancer-focused therapies.
Bristol-Myers Squibb
BMY
Mkt Cap116.66B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines in areas including oncology, directly competing with Enliven Therapeutics.
Pfizer
PFE
Mkt Cap149.38B
Pfizer Inc. has a broad range of oncology products that compete in the same market as Enliven Therapeutics' cancer treatments.
Astrazeneca
AZN
Mkt Cap277.22B
AstraZeneca PLC has a strong focus on oncology, with a portfolio that competes with Enliven Therapeutics in developing cancer therapies.
Novartis
NVS
Mkt Cap292.07B
Novartis AG focuses on innovative healthcare solutions, including oncology, where it competes with Enliven Therapeutics in the cancer treatment space.
Roche
RHHBY
Mkt Cap332.67B
Roche Holding AG, through its pharmaceuticals division, is a leader in oncology, directly competing with Enliven Therapeutics in cancer drug development.
Gilead Sciences
GILD
Mkt Cap155.93B
Gilead Sciences, Inc. is known for its strong presence in the oncology market, offering competitive therapies to those developed by Enliven Therapeutics.
AMGEN
AMGN
Mkt Cap191.7B
Amgen Inc. competes in the biopharmaceutical space, focusing on innovative therapies including oncology, which puts it in direct competition with Enliven Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap64.18B
Regeneron Pharmaceuticals, Inc. is involved in the discovery and development of pharmaceutical products for the treatment of cancer, among other diseases, competing with Enliven Therapeutics.

Regions

About

This actively managed exchange-traded fund, IMRA, offered by Bitwise, is crafted to generate consistent monthly income. Concurrently, it provides investors with a capped potential for gains linked to the share price performance of Marathon Digital Holdings, Inc. (MARA). The fund's methodology involves a synthetic covered call strategy, implemented using both standard exchange-traded and bespoke FLEX options. To back these derivative positions, it maintains U.S. Treasuries as collateral. It is crucial to note that the fund does not hold direct investments in MARA stock.
Show more...
CEO
Country
United States
ISIN
US0917487078

Listings

0 Comments

Share your thoughts

FAQ

What is Bitwise MARA Option Income Strategy stock price today?
The current price of IMRA is $17.48 USD — it has increased by +2.7% in the past 24 hours. Watch Bitwise MARA Option Income Strategy stock price performance more closely on the chart.
What is Bitwise MARA Option Income Strategy stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Bitwise MARA Option Income Strategy stocks are traded under the ticker IMRA.
What is Bitwise MARA Option Income Strategy market cap?
Today Bitwise MARA Option Income Strategy has the market capitalization of 1.04B
When is the next Bitwise MARA Option Income Strategy earnings date?
Bitwise MARA Option Income Strategy is going to release the next earnings report on August 19, 2026.
What were Bitwise MARA Option Income Strategy earnings last quarter?
IMRA earnings for the last quarter are -0.38 USD per share, whereas the estimation was -0.44 USD resulting in a +14.33% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bitwise MARA Option Income Strategy revenue for the last year?
Bitwise MARA Option Income Strategy revenue for the last year amounts to 0 USD.
What is Bitwise MARA Option Income Strategy net income for the last year?
IMRA net income for the last year is -178.05M USD.
Does Bitwise MARA Option Income Strategy pay dividends?
Yes, IMRA dividends are paid monthly. The last dividend per share was 0.17 USD. As of today, Dividend Yield (FWD)% is 11.74%.
In which sector is Bitwise MARA Option Income Strategy located?
Bitwise MARA Option Income Strategy operates in the Other sector.
When did Bitwise MARA Option Income Strategy complete a stock split?
The last stock split for Bitwise MARA Option Income Strategy was on February 24, 2023 with a ratio of 1:4.